OSTEOARTHRITIS
Knee osteoarthritis: Plasma rich in growth factor (Endoret) vs. hyaluronic acid (Durolane)
Arthroscopy. 2013 Oct;29(10):1635-4396 patients with osteoarthritis of the knee (OA) were randomized to evaluate the efficacy of 3 injections of plasma rich in growth factors (PRGF-Endoret) against a single injection of Durolane hyaluronic acid (HA) in treating knee OA. Treatments were primarily evaluated based on the percentage of patients having a 30% decrease and a 50% decrease in the summed score for all the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) subscales, and the Lequesne score. The evidence presented in this study indicated that plasma rich in growth factors (PRGF-Endoret) is safe and a significantly superior treatment to Durolane hyaluronic acid (HA).
Unlock the full ACE Report
You have access to {0} free articles per month.Click below to unlock and view this {1}
Unlock NowCritical appraisals of the latest, high-impact randomized controlled trials and systematic reviews in orthopaedics
Access to OrthoEvidence podcast content, including collaborations with the Journal of Bone and Joint Surgery, interviews with internationally recognized surgeons, and roundtable discussions on orthopaedic news and topics
Subscription to The Pulse, a twice-weekly evidence-based newsletter designed to help you make better clinical decisions
Exclusive access to original content articles, including in-house systematic reviews, and articles on health research methods and hot orthopaedic topics
Or upgrade today and gain access to all OrthoEvidence content for just $1.99 per week.
Already have an account? Log in
Subscribe to "The Pulse"
Evidence-Based Orthopaedics direct to your inbox.
{0} of {1} free articles
Become an OrthoEvidence Premium Member. Expand your perspective with high-quality evidence.
Upgrade Now
